Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,434,093	$ 1,676,813
Other current assets	127,065	121,774
Total current assets	1,561,158	1,798,587
Property and equipment, net	36,270	39,086
Operating lease right-of-use assets	51,631	53,251
Investments measured at fair value	296,243	304,317
Intangible assets, net	145,037	144,881
Other assets	46,307	49,482
Total assets	2,136,646	2,389,604
Current liabilities:
Accounts payable	50,035	37,830
Accrued expenses	119,329	167,129
Operating lease liabilities	11,348	11,693
Current portion of long-term debt (includes $27,490 and $26,940 accounted for under the fair value option at June 30, 2023 and March 31, 2023, respectively)	44,406	40,720
Other current liabilities	19,886	15,076
Total current liabilities	245,004	272,448
Liability instruments measured at fair value	103,723	63,546
Operating lease liabilities, noncurrent	51,812	53,476
Long-term debt, net of current portion (includes $187,140 and $180,700 accounted for under the fair value option at June 30, 2023 and March 31, 2023, respectively)	385,069	375,515
Other liabilities	16,899	17,032
Total liabilities	802,507	782,017
Commitments and contingencies (Note 10)
Shareholders' equity:
Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 767,137,861 and 760,143,393 shares issued and outstanding at June 30, 2023 and March 31, 2023, respectively	0	0
Additional paid-in capital	4,981,910	4,933,137
Accumulated deficit	(4,064,570)	(3,772,754)
Accumulated other comprehensive loss	(6,610)	(2,617)
Shareholders' equity attributable to Roivant Sciences Ltd.	910,730	1,157,766
Noncontrolling interests	423,409	449,821
Total shareholders' equity	1,334,139	1,607,587
Total liabilities and shareholders' equity	$ 2,136,646	$ 2,389,604